Guacetisal

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T6EKB9V2O2, chemically known as benzoic acid, 2-(acetyloxy)-, 2-methoxyphenyl ester but generally known as guacetisal, which bears US NIH Compound Identifier 68749. European Medicines Agency schedules Guacetisal in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07968MIG. The term GUACETISAL is an International Non-Proprietary Name. World Health Organization schedules guacetisal in its Anatomical Therapeutic Chemical (ATC) Classification. GUACETISAL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule guacetisal under HS 29182200 and SITC 51393. As of Q4 2014, GUACETISAL remains the US FDA Preferred Term for this commodity. Guacetisal bears US NLM identifiers UMLS ID C0120436 and NCI Concept Code C65821. SMILES: O(C1C(OC)CCCC1)C(=O)C1C(OC(=O)C)CCCC1.